mProX™ Human LPAR1 Stable Cell Line

Product Information

Target Protein

LPAR1

Target Family

Lysophospholipid Family

Target Protein Species

Human

Host Cell Type

HK-2;CHO-K1;HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Inflammation Research

Related Diseases

Pulmonary Fibrosis;Fibrosclerosis of Breast

Gene ID

Human: 1902

UniProt ID

Human: Q92633

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

LPAR1, known as the type I lysophosphatidic acid receptor, has been identified as a key regulator in various physiological and pathological processes. It has been found to regulate gastrointestinal motility through enteric glia, potentially contributing to severe motility disorders in humans such as Chronic Intestinal Pseudo-Obstruction (CIPO). In the context of diabetic nephropathy, LPA has been shown to induce epithelial-mesenchymal transition and renal tubular fibrosis via regulation of KLF5 through LPAR1. Furthermore, a reduction in LPAR1 expression in neuroblastoma has been associated with promoting tumor cell migration. Another study identified LPAR1 as a novel interaction partner of MRTF-A and Filamin A, suggesting its role in cellular signaling.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human LPAR1 Stable Cell Line (S01YF-0923-PY97). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Richard (Verified Customer)

How is LPAR1 associated with melanoma progression and therapy resistance? Apr 22 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

An LPAR1-axis has been identified as critical for melanoma invasion and intrinsic/acquired therapy resistance. This highlights the potential of targeting stem cell-like pathways that are hijacked by tumor cells in melanoma. Apr 22 2020

chat Emily (Verified Customer)

What is the potential interaction between the SARS-COV2 Envelope Protein (E) and LPAR1? Sep 06 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

LPAR1 is suggested to be a cell surface receptor for the SARS-COV2 Envelope Protein (E). This interaction could pave the way for studies aimed at understanding the biological significance of these interactions in SARS-COV disease and elucidating the signaling mechanisms. Sep 06 2023

Published Data

Fig.1 Silencing LPAR1 resulted in the suppression of LPA-triggered alterations in the expression profiles of epithelial-mesenchymal transition (EMT) markers and fibrogenic factors within HK-2 cells.

HK-2 cells underwent transfection with either control siRNA (siCon) or LPAR1 siRNA (siLPAR1) for 6 hours. Subsequently, the culture medium transitioned to serum-free conditions (SFM), followed by a 16-18 hour incubation and treatment with 20 μM LPA for 48 hours. Protein quantification of E-cadherin, vimentin, fibronectin, and α-SMA was conducted via Western blotting, utilizing ImageJ software for normalization against β-actin. Representative images (left) and bar graphs for quantitative analysis (right) are displayed (n = 3 independent experiments), with data represented as mean ± SEM. Significant differences: * p < 0.05 vs. siCon or siCon + BSA; # p < 0.05, ## p < 0.01, ### p < 0.005 vs. siCon + LPA.

Ref: Lee, Geon-Ho, et al. "Lysophosphatidic Acid Promotes Epithelial-Mesenchymal Transition in Kidney Epithelial Cells via the LPAR1/MAPK-AKT/KLF5 Signaling Pathway in Diabetic Nephropathy." International Journal of Molecular Sciences 23.18 (2022): 10497.

Pubmed: 36142408

DOI: 10.3390/ijms231810497

Research Highlights

Kurusu S, et al. "Expression of lysophosphatidic acid receptors in the rat uterus: cellular ." The Journal of veterinary medical science, 2023.
In this study, the researchers aimed to investigate the specific receptors of lysophosphatidic acid (LPA) present in the rat uterus during different stages of pregnancy. Through immunohistochemistry and quantitative analysis, the distribution and expression of LPA receptors (LPA1-6) were studied. The results showed that LPA3, LPA4, and LPA6 were significantly expressed, while LPA1 and LPA2 were less expressed. These receptors were present in multiple cell types within the uterus, with varying levels of expression during pregnancy. This study highlights the importance of understanding the diverse actions of LPA in the uterus and how it may vary depending on receptor subtype and reproductive state.
Pubmed: 37779089 DOI: 10.1292/jvms.23-0336

Hong JM, et al. "LPA1-mediated inhibition of CXCR4 attenuates CXCL12-induced signaling and cell ." Cell communication and signaling : CCS, 2023.
In this study, researchers aimed to investigate the potential regulatory impact of G protein-coupled receptor heteromerization on signal transduction. Specifically, they examined the interaction between CXC chemokine receptor 4 (CXCR4) and lysophosphatidic acid receptor 1 (LPA(1)), both overexpressed in many cancers. The formation and function of the CXCR4-LPA(1) heteromer were characterized using various assays. Results showed that CXCR4 and LPA(1) form heteromers in both recombinant and breast cancer cells. This heteromer had a selective effect on CXCR4 signaling, reducing its response to CXCL12, a ligand involved in metastasis. However, CXCR4 had no impact on LPA(1)-mediated signaling. In addition, LPA or LPA(1)-specific inhibitors hindered cell migration induced by CXCL12, indicating a potential therapeutic use of combined CXCR4 and LPA(1) inhibitors in cancer treatment. Overall, this study provides crucial insights into the regulatory mechanism of CXCR4 through heteromerization and suggests a potential therapeutic strategy for cancer and inflammatory diseases associated with these receptors.
Pubmed: 37749552 DOI: 10.1186/s12964-023-01261-7